$
8.410
-0.38(-4.323%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.910
Open
8.850
VWAP
--
Vol
936.00K
Mkt Cap
423.77M
Low
8.270
Amount
--
EV/EBITDA(TTM)
--
Total Shares
49.26M
EV
155.90M
EV/OCF(TTM)
--
P/S(TTM)
2.73
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
82.23M
+287.64%
--
--
110.02M
+354.69%
--
--
40.87M
+83.3%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for REGENXBIO Inc. (RGNX) for FY2025, with the revenue forecasts being adjusted by 2.91% over the past three months. During the same period, the stock price has changed by -12.49%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.91%
In Past 3 Month
Stock Price
Go Down
down Image
-12.49%
In Past 3 Month
9 Analyst Rating
up Image
273.72% Upside
Wall Street analysts forecast RGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGNX is 31.43 USD with a low forecast of 21.00 USD and a high forecast of 50.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
up Image
273.72% Upside
Current: 8.410
sliders
Low
21.00
Averages
31.43
High
50.00
Goldman Sachs
Paul Choi
Hold
Maintains
$14 → $12
2025-04-17
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$34
2025-03-21
Reason
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$52
2025-03-20
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$34
2025-03-20
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$36 → $34
2025-03-17
Reason
Morgan Stanley
Judah Frommer
Buy
Maintains
$22 → $24
2025-03-14
Reason
Morgan Stanley analyst Judah Frommer raised the firm's price target on Regenxbio to $24 from $22 and keeps an Overweight rating on the shares. The BLA for RGX-121 has been submitted, notes the analyst, who thinks Regenxbio remains in a "strong position" to commercialize RGX-121 and complete pivotal readouts for RGX-314 and RGX-202.

Valuation Metrics

The current forward P/E ratio for Regenxbio Inc (RGNX.O) is -8.97, compared to its 5-year average forward P/E of 2.30. For a more detailed relative valuation and DCF analysis to assess Regenxbio Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
2.30
Current PE
-8.97
Overvalued PE
23.15
Undervalued PE
-18.55

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.03
Current EV/EBITDA
12.84
Overvalued EV/EBITDA
3.60
Undervalued EV/EBITDA
-7.66

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
6.29
Current PS
1.52
Overvalued PS
9.64
Undervalued PS
2.94

Financials

Annual
Quarterly
FY2025Q1
YoY :
+469.79%
89.01M
Total Revenue
FY2025Q1
YoY :
-119.64%
12.13M
Operating Profit
FY2025Q1
YoY :
-109.61%
6.08M
Net Income after Tax
FY2025Q1
YoY :
-108.70%
0.12
EPS - Diluted
FY2025Q1
YoY :
-158.21%
32.61M
Free Cash Flow
FY2025Q1
YoY :
+32.46%
96.14
Gross Profit Margin - %
FY2025Q1
YoY :
-75.78%
-55.48
FCF Margin - %
FY2025Q1
YoY :
-101.68%
6.83
Net Margin - %
FY2025Q1
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
163.1K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
216.6K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
1.7M
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
14.1K
Volume
Months
6-9
1
332.8K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

RGNX News & Events

Events Timeline

2025-06-16 (ET)
2025-06-16
12:53:06
BofA expects no changes for Regenxbio regimen after competitor safety issue
select
2025-06-05 (ET)
2025-06-05
07:10:17
Regenxbio's RGX-202 shows efficacy in Phase 1/2 Duchenne trial
select
2025-05-19 (ET)
2025-05-19
16:09:07
Regenxbio signs strategic royalty monetization agreement for up to $250M
select
Sign Up For More Events

News

9.0
07-10PRnewswire
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
8.5
06-13SeekingAlpha
REGENXBIO registers 268K shares for resale
4.5
06-05Benzinga
Crude Oil Moves Higher; Ciena Posts Downbeat Earnings
Sign Up For More News

FAQ

arrow icon

What is Regenxbio Inc (RGNX) stock price today?

The current price of RGNX is 8.41 USD — it has decreased -4.32 % in the last trading day.

arrow icon

What is Regenxbio Inc (RGNX)'s business?

arrow icon

What is the price predicton of RGNX Stock?

arrow icon

What is Regenxbio Inc (RGNX)'s revenue for the last quarter?

arrow icon

What is Regenxbio Inc (RGNX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Regenxbio Inc (RGNX)'s fundamentals?

arrow icon

How many employees does Regenxbio Inc (RGNX). have?

arrow icon

What is Regenxbio Inc (RGNX) market cap?